Diana Tran

Rescheduling a Schedule I substance, and the Delta-8 controversy

Dec 17, 2021 | Blogs, Food / Beverage, Food and Beverage | 0 comments

Read time: 2 minutes

Introduction to drug scheduling in the US

Did you know that in the US, drugs and other chemicals are classified into 5 distinct categories depending on the drug’s acceptable medical use and its potential for abuse or dependency? Drugs federally classified as Schedule I substances by the US Drug Enforcement Administration (DEA) are considered to have the highest potential for abuse and for creating severe psychological and/or physical dependence. In addition to heroin, LSD and MDMA (ecstasy), cannabis is classified as a Schedule I substance in the Controlled Substance Act of 1970, which means it has no approved medical usage.

Let’s take a look at the movement to remove cannabis from its Schedule I classification at the federal level.

The movement to reclassify cannabis

In 2019, a bill was introduced to remove cannabis from the DEA’s Schedule I classification. While this bill cleared the US House of Representatives, it stalled in the GOP-controlled US Senate. In May 2021, a new bill was proposed by 2 GOP members of congress to legalize marijuana at the federal level and protect banks that service state-level cannabis businesses. By reclassifying cannabis as a Schedule III substance, the new bill would make scientific research easier, would allow the US Food and Drug Administration (FDA) to take control of consumer protection and normalize testing requirements and would enable the Alcohol and Tobacco Tax and Trade Bureau to help regulate cannabis nationally. The bill would not preempt the laws of any states where marijuana is not legalized, however.

The Delta-8 controversy and the emerging fight for federal legalization

The explosion in popularity of Delta-8 THC across the US, particularly in states where recreational marijuana remains illegal, is a notable trend. While Delta-8 buds look, smell and even taste like traditional psychoactive Delta-9 marijuana, Delta-8 is legal to buy and consume.1 Delta-8 provides the same psychoactive, mind-altering effects as Delta-9 marijuana, but it is currently unregulated, which means consumers can buy it as a legal alternative to marijuana. With signs that Delta-8 could take a bite out of the popularity of other products, such as CBD and nicotine vaping, a number of states have decided to ban it, which could become a turning point for marijuana legalization in the US. The question is, will Delta-8 make it into the fight for federal legalization of marijuana, or will it languish as a legal alternative for recreational users? It will be interesting to see the outcomes of the controversy. Stay tuned for more on this topic.

DISCLAIMER: THIS IS NOT INTENDED TO PROVIDE LEGAL ADVICE.

References
1. United States Drug Enforcement Administration (DEA), Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling
2. Alcohol Policy Information System (APIS). https://alcoholpolicy.niaaa.nih.gov/about-cannabis-policy
3. McDermott, T. Congress Keeps Taking Baby Steps on Marijuana Reform. JDSupra, May 27, 2021. https://www.jdsupra.com/legalnews/congress-keeps-taking-baby-steps-on-8779251/
4. Jaeger, K. Congressman Files First Federal Marijuana Reform Bill Of 2021. Marijuana Moment, January 21, 2021. https://www.marijuanamoment.net/congressman-files-first-federal-marijuana-reform-bill-of-2021/
5. Lessner, J. The Controversy Behind Delta-8 THC And Why Shoppers Are Buying It Up. mitú, April 20, 2021. https://wearemitu.com/wearemitu/things-that-matter/delta-8-thc-guide/
6. Yakowicz, W. Delta-8 THC Offers A Legal High, But Here’s Why The Booming Business May Soon Go Up In Smoke. Forbes, March 12, 2021. https://www.forbes.com/sites/willyakowicz/2021/03/12/delta-8-thc-offers-a-legal-high-but-heres-why-the-booming-business-may-soon-go-up-in-smoke/?sh=2a559ac95b3d
7. Ledger, E. US States Begin to Implement Bans on Delta-8 THC Cannabinoid. Canex, April 27, 2021. https://canex.co.uk/us-states-begin-to-implement-bans-on-delta-8-thc-cannabinoid/

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Diana Tran

Senior Applications Scientist, SCIEX. Diana Tran specializes in LC-MS/MS method development as an applications scientist at SCIEX. For the past 4 years, she has been actively involved in cannabis testing analysis and has had a hand in almost every cannabis method developed at SCIEX since then. Diana has been field tested in testing labs across the US, making connections in cannabis testing labs and acting as a resource for analytical chemists. She is always looking for new cannabuds—feel free to reach out and start a conversation.

0 Comments